CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 28 enrolled
Drug / intervention
Not specified
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02238795
NCT02238795N/ACompleted

Sepsis-Associated Purpura Fulminans International Registry - Europe

Jena University Hospital·observational·Posted Sep 12, 2014·Updated May 21, 2025

In Brief

An observational study for Sepsis. Completed, enrolled 28 participants across 3 sites.

Detailed Summary

Sepsis-associated Purpura fulminans (SAPF) is a rare life-threatening condition. It is characterized by multiple skin lesions which rapidly progress to necrosis and gangrene. SAPF is a manifestation of widespread clot formation in small blood vessels which emerges secondarily to severe bacterial and viral infections. The clinical presentation of SAPF is dominated by symptoms of severe sepsis and multiple organ failure which are further aggravated by the massive skin lesions. At present, there are no evidence-based guidelines for the medical management of SAPF. With numerous therapeutic approaches in use, there are no consistent comparisons of their efficacy. Altered role of causal pathogens following the introduction of meningococcal and pneumococcal prophylactic vaccines also remains to be investigated. The goal of the registry is comprehensive collection and evaluation of information concerning the epidemiology, morbidity, therapy and outcome of SAPF.

Study Details

Timeline

N/ACompletedFinished
201520162017201820192020202120222023202420252026
First PostedSep 12, 2014
Enrollment StartApr 1, 2016
Primary CompletionSep 30, 2020
TodayJul 2, 2026
Enrollment to primary: 4.5 yearsPosted 11.8 years ago